Lepzacitinib

DB21646InvestigationalSmall molecule

Lepzacitinib is a small molecule drug. The usage of the INN stem '-citinib' in the name indicates that Lepzacitinib is a Janus kinase inhibitor. Lepzacitinib is under investigation in clinical... Lepzacitinib is under investigation in clinical trial NCT05432596 (Study of ATI-1777 in Patients 12 to 65 Years Old With Mild to Severe Atopic Dermatitis).

Mechanism: Pharmacologically active on Tyrosine-protein kinase JAK3 and Tyrosine-protein kinase JAK1
Curator reviewed
Formula / weight: C₁₈H₂₁N₅O₃ · 355.398 g/mol (avg)
Code names: ATI-1777

Resolves to

Compound

UNIIDQN3V3R84UCAS2321488-47-3ChEMBLCHEMBL5856622ChEBI759867PubChem138624627

Structure

InChIKeyQQOPOYMFJLUSBI-GFCCVEGCSA-NSMILESCCOC(=O)C1=CN=C2NC=CC2=C1N[C@@H]1CCCN(C1)C(=O)CC#N

Targets

P52333JAK3P23458JAK1

What you can answer from here — as of September 23, 2026

2Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

1Clinical trialPhase, status and sponsor resolved per trial

4+ReferencesStructured and connected to the statements they support

Which drugs share a target with Lepzacitinib, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account